Eloxx Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eloxx Pharmaceuticals generated cash of -$31,845,000, which is more than the previous year. Cash used in financing activities reached the amount of $8,812,000 last year. Net change in cash is therefore -$23,099,000.
Cash Flow
| 2011 | -5.39M | -686.42K | 1.66M |
|---|---|---|---|
| 2012 | -4.38M | -450.49K | 3.22M |
| 2013 | -3.90M | -529.04K | 4.03M |
| 2016 | -3.67M | 0 | 1.15M |
| 2017 | -15.93M | -114K | 37.95M |
| 2018 | -31.36M | -317K | 56.18M |
| 2019 | -39.39M | -33.52M | 46.8M |
| 2020 | -28.16M | 33.79M | -3.43M |
| 2021 | -35.00M | 2.05M | 50.78M |
| 2022 | -31.84M | -66K | 8.81M |
ELOX Cash Flow Statement (2011 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 42.56M | 24.72M | 22.53M | 48.65M | 24.15M | 2.25M | 3.33M | 2.00M | 3.60M | 8.02M |
Operating activities | ||||||||||
Net income | -36.06M | -66.72M | -34.57M | -50.87M | -47.18M | -21.21M | -8.26M | -6.12M | -5.06M | 0 |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 695K | 960K | 571K | 559K | 216K | 39K | 93.39K | 293.62K | 258.02K | 143.27K |
Stock-based compensation expense | 3.02M | 9.16M | 8.66M | 11.33M | 0 | 101K | 156.67K | 724.69K | 766.00K | 750.36K |
| Deferred income tax benefit | 3.02M | 9.16M | 8.66M | 11.33M | 0 | 101K | 156.67K | 724.69K | 766.00K | 750.36K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.64M | -320K | -1.39M | 1.12M | -780K | -583K | -141.72K | 42.80K | 34.98K | 2.10K |
Cash generated by operating activities | -31.84M | -35.00M | -28.16M | -39.39M | -31.36M | -15.93M | -3.67M | -3.90M | -4.38M | -5.39M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -67.21M | 0 | -64K | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -66K | -89K | 0 | -40K | -235K | -237K | 0 | -529.04K | -4.46K | -2.02K |
Acquisitions Net | 0 | 2.14M | 0 | 2K | 0 | 123K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -66K | 2.05M | 33.79M | -33.52M | -317K | -114K | 0 | -529.04K | -450.49K | -686.42K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 47.71M | 0 | 32.88M | 55.73M | 17.00M | 1.15M | 4.04M | 3.22M | 1.65M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -11.38M | -4.58M | 15M | 0 | 2.5M | 0 | -12.02K | 0 | 0 |
Cash used in financing activities | 8.81M | 50.78M | -3.43M | 46.8M | 56.18M | 37.95M | 1.15M | 4.03M | 3.22M | 1.66M |
Net Change In Cash | -23.09M | 17.84M | 2.18M | -26.11M | 24.5M | 21.90M | -2.52M | -399.03K | -1.60M | -4.41M |
Cash at end of period | 19.46M | 42.56M | 24.72M | 22.53M | 48.65M | 24.15M | 810.80K | 1.60M | 2.00M | 3.60M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |